| pathology | treatment | patient | Demonstrated benefit and harm | k | | | |
|---|
| acute coronary syndrome | diltiazem | not classified | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Göbel (Dutch study), 1995 | diltiazem intravenously (n=129) vs. glyceryl trinitrate intravenously (n=0) | patients with unstable angina | double blind Parallel groups Sample size: 129/0 Primary endpoint: refractory angina or myocardial infarction FU duration: ND | | DRS, 1986 | diltiazem 90 mg every six hours up to 14 days (n=287) vs. placebo (n=289) | patients with non-Q-wave myocardial infarct, 24 to 72 hours after the onset of infarction | double blind Sample size: 287/289 Primary endpoint: reinfarction FU duration: ND |
|
| acute coronary syndrome | nifedipine | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| HINT (nifedipine vs metoprolol), 1988 | nifedipine (n=-9) vs. metoprolol (n=-9) | patients with unstable angina not pretreated with a beta-blocker and of nifedipine | ND Parallel groups Sample size: -9/-9 Primary endpoint: recurrent ischemia or myocardial infarction within 48 h FU duration: ND |
|
| acute myocardial infarction | diltiazem | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Machecourt, 1986 | diltiazem vs | | | all cause death 0.49 [0.09; 2.50] confirmed myocardial infarction 0.97 [0.84; 1.13] |
| Trial | Treatments | Patients | Method |
|---|
| Machecourt, 1986 | Diltiazem 360mg IV/24h plus 360mh/24h orally (n=38) vs. (n=37) | | single blind Parallel groups Sample size: 38/37 Primary endpoint: infract size FU duration: 21 days |
|
| acute myocardial infarction | diltiazem | not classified | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Gibson, 1986 | diltiazem vs placebo | | | all cause death 1.23 [0.52; 2.93] | | MDPIT, 1988 | diltiazem vs placebo | | | all cause death 1.00 [0.82; 1.22] cardiac death 1.03 [0.81; 1.30] reinfarction 0.85 [0.66; 1.10] | | Zannad, 1988 | diltiazem vs placebo | | | confirmed myocardial infarction 1.06 [0.94; 1.20] |
| Trial | Treatments | Patients | Method |
|---|
| Gibson, 1986 | Diltiazem 90mgx4 (n=287) vs. placebo (n=289) | | double blind Parallel groups Sample size: 287/289 Primary endpoint: reinfarction FU duration: 14 days | | MDPIT, 1988 | Diltiazem 60mgx4 (n=1234) vs. placebo (n=1232) | Patient aged 25 to 75 years, admitted to coronary care units with a documented acute myocardial infarction | Double blind Parallel groups Sample size: 1234/1232 Primary endpoint: NA FU duration: 25 months (at least 12 months) | | Zannad, 1988 | Diltiazem 10-20mg/h IV, 4x60mg orraly (n=17) vs. placebo (n=17) | | double blind Parallel groups Sample size: 17/17 Primary endpoint: infract size FU duration: |
|
| acute myocardial infarction | nifedipine | not classified | versus No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Muller, 1984 | nifedipine vs | | | all cause death 3.31 [0.71; 15.51] confirmed myocardial infarction 0.99 [0.86; 1.13] | | Gordon, 1984 | nifedipine vs | | | all cause death NaN [NaN; NaN] confirmed myocardial infarction 1.00 [1.00; 1.00] | | MI study group, 1979 | nifedipine vs | | | |
| Trial | Treatments | Patients | Method |
|---|
| Muller, 1984 | Nifedipine 20mgx6 (n=93) vs. (n=88) | | double blind Parallel groups Sample size: 93/88 Primary endpoint: infarct development FU duration: 14 days | | Gordon, 1984 | Nifedipine 10 mgx4 (n=13) vs. (n=13) | | single blind Parallel groups Sample size: 13/13 Primary endpoint: haemodynamics FU duration: 1 day | | MI study group, 1979 | Nifedipine 3-4x60mg (n=904) vs. (n=888) | | open Parallel groups Sample size: 904/888 Primary endpoint: mortality FU duration: |
|
| acute myocardial infarction | nifedipine | not classified | versus placebo or control No demonstrated result for efficacy | 11 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Eisenberg, 1985 | nifedipine vs placebo | | | all cause death NaN [NaN; NaN] confirmed myocardial infarction 1.22 [NaN; NaN] | | Bradagan, 1986 | nifedipine vs placebo | | | all cause death 1.59 [0.53; 4.74] confirmed myocardial infarction 1.24 [0.81; 1.89] | | Jaffe, 1987 | nifedipine vs placebo | | | all cause death ∞ [NaN; ∞] confirmed myocardial infarction 1.00 [1.00; 1.00] | | Gottlieb, 1988 | nifedipine vs placebo | | | all cause death 1.06 [0.28; 4.07] confirmed myocardial infarction 1.12 [0.97; 1.29] | | Erbel, 1988 | nifedipine vs placebo | | | all cause death 1.69 [0.65; 4.41] confirmed myocardial infarction 1.00 [1.00; 1.00] | | SPRINT I, 1988 | nifedipine vs placebo | | | all cause death 1.01 [0.73; 1.42] cardiac death 1.01 [0.70; 1.47] reinfarction 0.92 [0.63; 1.34] | | SPRINT II, 1993 | nifedipine vs placebo | | | all cause death 1.16 [0.90; 1.51] confirmed myocardial infarction 0.96 [0.92; 1.01] | | Loogna, 1985 | nifedipine vs placebo | | | confirmed myocardial infarction 1.00 [1.00; 1.00] | | TRENT (Wilcox), 1986 | nifedipine vs placebo | | | confirmed myocardial infarction 1.00 [0.95; 1.04] | | Walker, 1988 | nifedipine vs placebo | | | confirmed myocardial infarction 0.98 [0.86; 1.11] | | Sirnes, 1984 | nifedipine vs placebo | | | confirmed myocardial infarction 0.92 [0.77; 1.09] |
| Trial | Treatments | Patients | Method |
|---|
| Eisenberg, 1985 | Nifedipine 20mgx4 (n=25) vs. placebo (n=25) | patients with nontransmural myocardial infarction | double blind Parallel groups Sample size: 25/25 Primary endpoint: chest pain FU duration: 12 days | | Bradagan, 1986 | Nifedipine 10mgx4 (n=60) vs. placebo (n=61) | patients with suspected acute myocardial infarction within 6hrs | double blind Parallel groups Sample size: 60/61 Primary endpoint: infract size FU duration: 2 days | | Jaffe, 1987 | Nifedipine 6x20mg (n=13) vs. placebo (n=9) | patients with acute myocardial infarction | single blind Parallel groups Sample size: 13/9 Primary endpoint: FU duration: 7 days | | Gottlieb, 1988 | Nifedipine 10 to 30mgx4 (n=64) vs. placebo (n=68) | | double blind Parallel groups Sample size: 64/68 Primary endpoint: LV function FU duration: 42 days | | Erbel, 1988 | Nifedipine 20mgx3 (n=74) vs. placebo (n=75) | patients with acute myocardial infarction | double blind Parallel groups Sample size: 74/75 Primary endpoint: infract size FU duration: hospital stay | | SPRINT I, 1988 | Nifedipine 10mgx3 (n=1130) vs. placebo (n=1146) | patient surviving MI 7 and 21 days after admission | Double blind Parallel groups Sample size: 1130/1146 Primary endpoint: mortality FU duration: 1 year | | SPRINT II, 1993 | Nifedipine 20mgx3 started within 3hr of hopsital admission for 6 months (n=682) vs. placebo (n=676) | men and women with suspected acute MI | Double blind Parallel groups Sample size: 682/676 Primary endpoint: two primary endpoints: non fatal MI and mortality FU duration: 6 months | | Loogna, 1985 | Nifedipine 4x10mg (n=23) vs. placebo (n=34) | patients with acute myocardial infarction within 6 h from onset of symptoms | double blind Parallel groups Sample size: 23/34 Primary endpoint: infract size FU duration: | | TRENT (Wilcox), 1986 | Nifedipine 4x10mg (n=2240) vs. placebo (n=2251)
| patients with suspected myocardial infarction
| double blind Parallel groups Sample size: 2240/2251 Primary endpoint: mortality FU duration: 28 days
| | Walker, 1988 | Nifedipine 6x10mg for 48hrs (n=217) vs. placebo (n=217) | patients with suspected myocardial infarction within six hours from the onset of chest pain | double blind Parallel groups Sample size: 217/217 Primary endpoint: infract size FU duration: | | Sirnes, 1984 | Nifedipine 5x10mg (n=112) vs. placebo (n=115)
| patients with suspected acute myocardial infarction
| double blind Parallel groups Sample size: 112/115 Primary endpoint: infract size FU duration: 42 days
|
|
| acute myocardial infarction | verapamil | not classified | versus placebo or control No demonstrated result for efficacy | 6 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Bussman, 1984 | verapamil vs control | | | all cause death NaN [NaN; NaN] confirmed myocardial infarction 1.00 [1.00; 1.00] | | DAVIT I, 1984 | verapamil vs placebo | | | | | Crea, 1985 | verapamil vs placebo | | | all cause death 0.00 [0.00; NaN] confirmed myocardial infarction 1.00 [1.00; 1.00] | | DAVIT II, 1990 | verapamil vs placebo | | | all cause death 0.82 [0.63; 1.05] cardiac death 0.80 [0.61; 1.05] | | CRIS, 1996 | verapamil vs placebo | | | all cause death 1.06 [0.64; 1.73] cardiac death 0.97 [0.54; 1.75] reinfarction 0.81 [0.54; 1.22] | | Danish study, 1984 | verapamil vs placebo | | | confirmed myocardial infarction 0.99 [0.92; 1.07] |
| Trial | Treatments | Patients | Method |
|---|
| Bussman, 1984 | Verapamil 5 to 10 mg/h IV (n=29) vs. no treatment (n=25) | | open Parallel groups Sample size: 29/25 Primary endpoint: infract size FU duration: 2 days | | DAVIT I, 1984 | verapamil 120mgx3 (n=1751) vs. placebo (n=1747) | | Double blind Parallel groups Sample size: 1751/1747 Primary endpoint: all-cause mortality FU duration: 6 months | | Crea, 1985 | verapamil 80mgx3 (n=8) vs. placebo (n=9) | patients admitted to the coronary care unit with transmural acute myocardial infarction | single blind Parallel groups Sample size: 8/9 Primary endpoint: angina and reinfarction FU duration: 10 days | | DAVIT II, 1990 | verapamil 120mgx3 for 18 months (n=878) vs. placebo (n=897) | patients <76years with diagnosis of acute MI | Double blind Parallel groups Sample size: 878/897 Primary endpoint: all-cause mortality and firstmajor event FU duration: 16 months | | CRIS, 1996 | verapamil retard 360 mg daily (n=531) vs. placebo (n=542) | patients admitted for acute myocardial infarction | Double blind Parallel groups Sample size: 531/542 Primary endpoint: all-cause mortality FU duration: 23.5 months | | Danish study, 1984 | verapamil 0.1mg/kg IV plus 3x120mg orally (n=1729) vs. placebo (n=1718) | patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction | double blind Parallel groups Sample size: 1729/1718 Primary endpoint: mortality FU duration: 12 months |
|
| heart failure | amlodipine | not classified | versus placebo or no treatment No demonstrated result for efficacy | 7 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PRAISE, 1996 | amlodipine vs placebo | | | all-cause death 0.87 [0.74; 1.01] cardiovascular event 0.92 [0.80; 1.06] | | PRAISE II , 2000 | Amlodipine vs placebo | | | all-cause death 1.06 [0.92; 1.22] | | amlodipine vs control | | | | | Smith, 1994 | amlodipine vs control | | | | | amlodipine vs control | | | | | amlodipine vs control | | | | | amlodipine vs control | | | |
| Trial | Treatments | Patients | Method |
|---|
| PRAISE, 1996 | amlodipine 10 mg once daily (n=571) vs. placebo (n=582) | patients with severe chronic heart failure and ejection fractions of less than 30 percent appl | Double blind Parallel groups Sample size: 571/582 Primary endpoint: death from any cause and hospitalization FU duration: median 13.8 mo (range 6-33 mo) | | PRAISE II , 2000 | Amlodipine (n=826) vs. placebo (n=826) | heart failure in non ischemic cardiomyopathy | Sample size: 826/826 Primary endpoint: FU duration: up to 4 years | | Packer, 1991 | amlodipine (n=-9) vs. (n=-9) | CHD multiple cause, NYHA class II-III | Double blind Sample size: -9/-9 Primary endpoint: FU duration: 2 months | | Smith, 1994 | amlodipine (n=-9) vs. (n=-9) | CHD multiple cause, NYHA class II-III | Double blind Sample size: -9/-9 Primary endpoint: FU duration: 3 months | | Udelson, 1996 | amlodipine (n=-9) vs. (n=-9) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II-III | Double blind Sample size: -9/-9 Primary endpoint: FU duration: 3 months | | Binkley, 1996 | amlodipine (n=-9) vs. (n=-9) | CHD multiple cause, NYHA class II-III | Double blind Sample size: -9/-9 Primary endpoint: FU duration: 3 months | | Ghali, 1997 | amlodipine (n=-9) vs. (n=-9) | CHD multiple cause, NYHA class III-IV | Double blind Sample size: -9/-9 Primary endpoint: FU duration: 3 months |
|
| heart failure | diltiazem | not classified | versus placebo or no treatment No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Liao , 1998 | Diltiazem vs placebo | all-cause death 0.31 [0.10; 0.94] hospitalization for heart failure 0.26 [0.14; 0.46] | | | | DiDi, 1996 | diltiazem vs placebo | | | all-cause death 1.02 [0.37; 2.80] |
| Trial | Treatments | Patients | Method |
|---|
| Liao , 1998 | diltiazem 30mg twice daily (n=114) vs. control (vitamin B1 30mg twice daily) (n=107) | patients with dilated cardiomyopathy | Simple aveugle Parallel groups Sample size: 114/107 Primary endpoint: ventricular function FU duration: 6 months | | DiDi, 1996 | diltiazem 60mg three times daily (n=92) vs. placebo (n=94) | idiopathic dilated cardiomyopathy and LVEF<0.50 | Double blind Parallel groups Sample size: 92/94 Primary endpoint: mortality and transplant listing FU duration: 24 months |
|
| heart failure | felodipine | not classified | versus placebo or no treatment No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| VHeFT III, 1997 | felodipine vs placebo | | | all-cause death 1.08 [0.67; 1.73] | | Kassis, 1987 | felodipine vs placebo | | | | | Littler, 1995 | Felodipine vs placebo | | | all-cause death 1.35 [0.23; 7.95] | | felodipine vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| VHeFT III, 1997 | felodipine 5mg twice daily (n=224) vs. placebo (n=226) | male patient over 18 years with heart failure | Double blind Parallel groups Sample size: 224/226 Primary endpoint: exercise tolerance FU duration: mean 18mo (range 3-39 mo) | | Kassis, 1987 | felodipine 10 mg twice daily (n=18) vs. placebo (n=18) | patients on conventional therapy for severe CHF | Double blind Cross over Sample size: 18/18 Primary endpoint: haemodynamic FU duration: 3 weeks | | Littler, 1995 | felodipine extended release 2.5-10mg twice daily (in addition to existing background medication) for 12 weeks (n=132) vs. placebo (n=119) | patients with NYHA class II-III stable congestive heart failure despite treatment with ACE inhibitors, diuretic and digoxin or any combinaison of these drugs | Double blind Parallel groups Sample size: 132/119 Primary endpoint: exercise tolerance FU duration: 3 months | | Kassis, 1990 | felopidine 10 mg BID (n=10) vs. placebo (n=10) | severe congestive heart failure (NYHA class III) | Double blind Parallel groups Sample size: 10/10 Primary endpoint: haemodynamic FU duration: 6 months |
|
| heart failure | felodipine | not classified | versus angiotensin-converting enzyme inhibitors No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| felodipine vs enalapril | | | | | felodipine vs enalapril | | | |
| Trial | Treatments | Patients | Method |
|---|
| Dunselman, 1990 | felodipine 10 mg b.i.d. (n=9) vs. enalapril 10 mg b.i.d. (n=11) | patients with congestive heart failure due to ischaemic heart disease and NYHA class III | Double blind Sample size: 9/11 Primary endpoint: cardiopulmonary exercise tests FU duration: 4 months | | De Vries, 1995 | felodipine 2.5mg twice daily (n=22) vs. enalapril 2.5mg twice daily (n=24) | patients NYHA class II-III with left ventricular ejection fraction <0.4, symptoms of CHD despite therapy with diuretics and digoxin | Double blind Parallel groups Sample size: 22/24 Primary endpoint: cardiopulmonary exercise tests FU duration: 4 months |
|
| heart failure | isradipine | not classified | versus placebo or no treatment No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| isradipine vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Van den Toren, 1996 | isradipine up to 5mg 3 times daily (n=19) vs. placebo (n=0) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II-III, FE<40% | Double blind Parallel groups Sample size: 19/0 Primary endpoint: Hemodynamic FU duration: 3 months |
|
| heart failure | mibefradil | not classified | versus placebo or no treatment No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| MACH 1, 2000 | mibefradil vs placebo | hospitalization for heart failure 0.85 [0.75; 0.97] | | all-cause death 1.10 [0.96; 1.25] cardiovascular death 1.08 [0.94; 1.24] |
| Trial | Treatments | Patients | Method |
|---|
| MACH 1, 2000 | mibefradil titrated up to100mg daily (n=1295) vs. placebo (n=1295) | Patients with moderate to severe congestive heart failure (NYHA class II to IV and left ventricular fraction ,35%).pj | Double aveugle Parallel groups Sample size: 1295/1295 Primary endpoint: all-cause mortality FU duration: 1.6 years |
|
| heart failure | nicardipine | not classified | versus placebo or no treatment No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| nicardipine vs control | | | | | nicardipine vs control | | | |
| Trial | Treatments | Patients | Method |
|---|
| Gheorghiade, 1991 | nicardipine (n=-9) vs. (n=-9) | CHD multiple cause, NYHA class III | Double blind Sample size: -9/-9 Primary endpoint: FU duration: 4 months | | Abrams, 1993 | nicardipine (n=-9) vs. (n=-9) | CHD multiple cause, NYHA class III-IV | Double blind Sample size: -9/-9 Primary endpoint: FU duration: 4 months |
|
| heart failure | nisoldipine | not classified | versus placebo or no treatment No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Nisoldipine vs placebo | | | | | nisoldipine vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Gaudron, 1996 | Nisoldipine (n=-9) vs. placebo (n=-9) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II, FE<=45% | Sample size: -9/-9 Primary endpoint: FU duration: 18 months | | Rousseau, 1994 | nisoldipine 20 mg once daily (n=16) vs. placebo (n=16) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II | Double blind Sample size: 16/16 Primary endpoint: myocardial perfusion and neuro-hormonal status FU duration: 2 months |
|
| heart failure | nisoldipine | not classified | versus angiotensin-converting enzyme inhibitors No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| nisoldipine vs captopril | | | |
| Trial | Treatments | Patients | Method |
|---|
| Schofer, 1990 | nisoldipine (2 X 10 mg) (n=24) vs. captopril (3 X 25 mg) (n=0) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II-III | Double blind Sample size: 24/0 Primary endpoint: haemodynamic response FU duration: 3 months |
|
| post myocardial infarction | diltiazem | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| MDPIT, 1988 | diltiazem vs placebo | | | all cause death 1.00 [0.82; 1.22] cardiac death 1.03 [0.81; 1.30] reinfarction 0.85 [0.66; 1.10] |
| Trial | Treatments | Patients | Method |
|---|
| MDPIT, 1988 | Diltiazem 60mgx4 (n=1234) vs. placebo (n=1232) | Patient aged 25 to 75 years, admitted to coronary care units with a documented acute myocardial infarction | Double blind Parallel groups Sample size: 1234/1232 Primary endpoint: NA FU duration: 25 months (at least 12 months) |
|
| post myocardial infarction | nifedipine | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| MI study group, 1979 | nifedipine vs | | | |
| Trial | Treatments | Patients | Method |
|---|
| MI study group, 1979 | Nifedipine 3-4x60mg (n=904) vs. (n=888) | | open Parallel groups Sample size: 904/888 Primary endpoint: mortality FU duration: |
|
| post myocardial infarction | nifedipine | not classified | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| SPRINT I, 1988 | nifedipine vs placebo | | | all cause death 1.01 [0.73; 1.42] cardiac death 1.01 [0.70; 1.47] reinfarction 0.92 [0.63; 1.34] | | SPRINT II, 1993 | nifedipine vs placebo | | | all cause death 1.16 [0.90; 1.51] confirmed myocardial infarction 0.96 [0.92; 1.01] |
| Trial | Treatments | Patients | Method |
|---|
| SPRINT I, 1988 | Nifedipine 10mgx3 (n=1130) vs. placebo (n=1146) | patient surviving MI 7 and 21 days after admission | Double blind Parallel groups Sample size: 1130/1146 Primary endpoint: mortality FU duration: 1 year | | SPRINT II, 1993 | Nifedipine 20mgx3 started within 3hr of hopsital admission for 6 months (n=682) vs. placebo (n=676) | men and women with suspected acute MI | Double blind Parallel groups Sample size: 682/676 Primary endpoint: two primary endpoints: non fatal MI and mortality FU duration: 6 months |
|
| post myocardial infarction | verapamil | not classified | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| DAVIT I, 1984 | verapamil vs placebo | | | | | DAVIT II, 1990 | verapamil vs placebo | | | all cause death 0.82 [0.63; 1.05] cardiac death 0.80 [0.61; 1.05] | | CRIS, 1996 | verapamil vs placebo | | | all cause death 1.06 [0.64; 1.73] cardiac death 0.97 [0.54; 1.75] reinfarction 0.81 [0.54; 1.22] | | Danish study, 1984 | verapamil vs placebo | | | confirmed myocardial infarction 0.99 [0.92; 1.07] |
| Trial | Treatments | Patients | Method |
|---|
| DAVIT I, 1984 | verapamil 120mgx3 (n=1751) vs. placebo (n=1747) | | Double blind Parallel groups Sample size: 1751/1747 Primary endpoint: all-cause mortality FU duration: 6 months | | DAVIT II, 1990 | verapamil 120mgx3 for 18 months (n=878) vs. placebo (n=897) | patients <76years with diagnosis of acute MI | Double blind Parallel groups Sample size: 878/897 Primary endpoint: all-cause mortality and firstmajor event FU duration: 16 months | | CRIS, 1996 | verapamil retard 360 mg daily (n=531) vs. placebo (n=542) | patients admitted for acute myocardial infarction | Double blind Parallel groups Sample size: 531/542 Primary endpoint: all-cause mortality FU duration: 23.5 months | | Danish study, 1984 | verapamil 0.1mg/kg IV plus 3x120mg orally (n=1729) vs. placebo (n=1718) | patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction | double blind Parallel groups Sample size: 1729/1718 Primary endpoint: mortality FU duration: 12 months |
|
